The genetic complexity of common cancers and the promise of personalized medicine: Is there any hope?

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 274-282

  Arnedos, Monica ^a,b   Vielh, Philippe ^b,c,d   Soria, Jean Charles ^b,e,f   Andre, Fabrice ^a,b,f  

^a Gustave Roussy Cancer Campus ^*  (France)

^b Universite Paris Sud   (France)

^c Translational Research Laboratory   (France)

^d Gustave Roussy Cancer Campus   (France)

^e Gustave Roussy Cancer Campus   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

personalized medicine; stratified therapy; targeted therapy

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; CRIZOTINIB; DACARBAZINE; DNA; EML4 ALK FUSION PROTEIN; ERLOTINIB; GEFITINIB; HYBRID PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTOME; UNCLASSIFIED DRUG; VEMURAFENIB;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CARCINOID; CHROMOSOME NUMBER; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLONE; COLORECTAL CANCER; COPY NUMBER VARIATION; DNA SEQUENCE; DRIVER MUTATION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOMICS; GLIOMA; HUMAN; HUMAN GENOME; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MELANOMA; METASTASIS; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NEOPLASM; ONCOGENE K RAS; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOMATIC MUTATION; STOMACH CANCER; TESTIS CARCINOMA; WHOLE GENOME SEQUENCING;

PERSONALIZED MEDICINE; STRATIFIED THERAPY; TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT SELECTION; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84890282111     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4276     Document Type: Review

References (72)

1. Lander ES, Linton LM, Birren B, et al., Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
2. Dancey JE, Bedard PL, Onetto N, et al., The genetic basis for cancer treatment decisions. Cell 2012; 148: 409-420.
3. Meyerson M, Gabriel S, Getz G,. Advances in understanding cancer genomes through second-generation sequencing. Nature Rev Genet 2010; 11: 685-696.
4. Phimister EG, Feero WG, Guttmacher AE,. Realizing genomic medicine. N Engl J Med 2012; 366: 757-759.
5. Ding L, Ley TJ, Larson DE, et al., Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
6. Ross-Innes CS, Stark R, Teschendorff AE, et al., Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481: 389-393.
7. Roychowdhury S, Iyer MK, Robinson DR, et al., Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra21.
8. Vogel CL, Cobleigh MA, Tripathy D, et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
9. Romond EH, Perez EA, Bryant J, et al., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
10. Marchetti A, Martella C, Felicioni L, et al., EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-865.
11. Flaherty KT, Puzanov I, Kim KB, et al., Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
12. Vesely MD, Schreiber RD,. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284: 1-5.
13. Curtis C, Shah SP, Chin SF, et al., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
14. Stratton MR, Campbell PJ, Futreal PA,. The cancer genome. Nature 2009; 458: 719-724.
15. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
16. Greenman C, Stephens P, Smith R, et al., Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
17. Sjoblom T, Jones S, Wood LD, et al., The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
18. Wood LD, Parsons DW, Jones S, et al., The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
19. Parsons DW, Li M, Zhang X, et al., The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-439.
20. Ding L, Getz G, Wheeler DA, et al., Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
21. Kan Z, Jaiswal BS, Stinson J, et al., Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
22. Pleasance ED, Stephens PJ, O'Meara S, et al., A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-190.
23. Pleasance ED, Cheetham RK, Stephens PJ, et al., A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-196.
24. de Klein A, van Kessel AG, Grosveld G, et al., A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765-767.
25. Cohen Y, Xing M, Mambo E, et al., BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-627.
26. MacConaill LE, Campbell CD, Kehoe SM, et al., Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4: e7887.
27. Chapman MA, Lawrence MS, Keats JJ, et al., Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
28. Forbes SA, Bindal N, Bamford S, et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
29. Stephens PJ, Tarpey PS, Davies H, et al., The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
30. Shibata D. Cancer,. Heterogeneity and tumor history. Science 2012; 336: 304-305.
31. Campbell PJ, Yachida S, Mudie LJ, et al., The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
32. Yachida S, Jones S, Bozic I, et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
33. Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
34. Yap TA, Gerlinger M, Futreal PA, et al., Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps10.
35. Turner NC, Reis-Filho JS,. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012; 13: e178-e185.
36. Jakobsen JN, Sorensen JB,. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol 2012; 69: 289-299.
37. Vignot S, Frampton GM, Soria JC, et al., Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013; 31: 2167-2172.
38. Boca SM, Kinzler KW, Velculescu VE, et al., Patient-oriented gene set analysis for cancer mutation data. Genome Biol 2010; 11: R112.
39. Schiller JH, Harrington D, Belani CP, et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
40. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
41. Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
42. Fukuoka M, Yano S, Giaccone G, et al., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-2246.
43. Herbst RS, Giaccone G, Schiller JH, et al., Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
44. Giaccone G, Herbst RS, Manegold C, et al., Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777-784.
45. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
46. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
47. Travis WD, Brambilla E, Riely GJ,. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31: 992-1001.
48. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
49. Bhatia S, Tykodi SS, Thompson JA,. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23: 488-496.
50. Chapman PB, Einhorn LH, Meyers ML, et al., Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
51. Middleton MR, Grob JJ, Aaronson N, et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
52. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
53. Gorden A, Osman I, Gai W, et al., Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003; 63: 3955-3957.
54. Sosman JA, Kim KB, Schuchter L, et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
55. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
56. Muranen T, Selfors LM, Worster DT, et al., Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21: 227-239.
57. Chandarlapaty S, Sawai A, Scaltriti M, et al., AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.
58. Mittendorf EA, Wu Y, Scaltriti M, et al., Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 7381-7388.
59. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
60. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
61. Sequist LV, Waltman BA, Dias-Santagata D, et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
62. Johannessen CM, Boehm JS, Kim SY, et al., COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.
63. Choi YL, Soda M, Yamashita Y, et al., EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
64. Maheswaran S, Sequist LV, Nagrath S, et al., Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
65. Diehl F, Li M, Dressman D, et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005; 102: 16368-16373.
66. Higgins MJ, Jelovac D, Barnathan E, et al., Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012; 18: 3462-3469.
67. Board RE, Ellison G, Orr MC, et al., Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 2009; 101: 1724-1730.
68. Yap TA, Sandhu SK, Workman P, et al., Envisioning the future of early anticancer drug development. Nature Rev Cancer 2010; 10: 514-523.
69. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al., Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
70. Arnedos M, Scott V, Job B, et al., Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer 2012; 48: 2293-2299.
71. Wagle N, Berger MF, Davis MJ, et al., High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012; 2: 82-93.
72. Andre F, Bachelot T, Campone M, et al., Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): a prospective multicentric trial (SAFIR01). J Clin Oncol 2013; 31 (Suppl): abstract 511.